Snell, Cameron E. http://orcid.org/0000-0001-7847-3041
Gough, Madeline
Liu, Cheng
Middleton, Kathryn
Pyke, Christopher
Shannon, Catherine
Woodward, Natasha
Hickey, Theresa E.
Armes, Jane E.
Tilley, Wayne D.
Funding for this research was provided by:
Royal College of Pathologists of Australasia (RCPA Foundation Postgraduate Research Fellowship)
Department of Health | National Health and Medical Research Council (PhD scholarship, 1130077, 1130077)
Royal Adelaide Hospital (Career Development Fellowship)
National Breast Cancer Foundation (PS-15-041)
Article History
Received: 15 May 2018
Revised: 14 October 2018
Accepted: 20 October 2018
First Online: 9 November 2018
Competing interests
: KM reports receiving travel expenses from Roche. CS reports receiving compensation for being on advisory boards for Roche and AstraZeneca. NW reports stock ownership (CSL), receiving travel/expenses from Roche and research funding from Medivation. The remaining authors declare that they have no conflict of interest.
: for patient-derived explant studies, tumour samples were obtained following informed consent from women undergoing surgery for breast cancer at the Burnside War Memorial Hospital, Adelaide. This study was approved by the University of Adelaide Human Research Ethics Committee (approval numbers: H-065-2005; H-169-2011). For the retrospective cohort, the use of clinical information and tumour blocks was approved by the Mater Health Services Human Research Ethics Committee with a waiver of consent (approval number: HREC/15/MHS/123). The study was performed in accordance with the Declaration of Helsinki.
: To protect patient privacy, all patient data have been de-identified and reported in aggregate. De-identified patient data are available from the authors on request by e-mail.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).